Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

    Is Gilead (GILD) Poised for a Beat This Earnings Season?

    Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

      Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

      Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

        Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

        At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

          Perrigo Company Gets FDA Approval for Generic Topical Gel

          Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

            Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

            Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

              J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

              Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                  Can Novartis (NVS) Spring a Surprise This Earnings Season?

                  Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

                    Mark Vickery headshot

                    Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

                    Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

                      Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

                      Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

                        Sweta Killa headshot

                        IPO Market Back On Track: ETFs to Tap

                        After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

                          Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                          Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

                            Novartis' Cosentyx Superior to Stelara in Psoriasis Study

                            Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

                              Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

                              Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                                Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                                Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                                  Bayer Starts Phase III Study for Uterine Fibroids' Candidate

                                  Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

                                    Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

                                    Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

                                      Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

                                        Gilead's (GILD) HCV Drug Application Accepted in the EU

                                        Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                                          Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                                          Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                                            AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                                            AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                                              Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                                              Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                                                J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                                                Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                                                  AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?

                                                  AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.